ScreenerHero

KARD Kardigan, Inc.

NAS · US · Healthcare · Biotechnology · kardigan.bio
13.83USD+2.52%Mkt Cap: 1.29B $P/E: —

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.29B USD
Enterprise Value677.12M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-191.94M USD
Revenue/Share—
Last Price13.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees241
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.22
PEG—
EV/EBITDA-2.55
EV/Revenue—
P/S—
P/B2.05
EPS (TTM)-10.65
EPS (Forward)-3.20
52W Range
12.3210% of range27.00
52W High27.00 USD
52W Low12.32 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE76.67%
ROA-49.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-151.06M USD
CapEx (TTM)6.64M USD
FCF Margin—
FCF Yield—
Net Debt-584.25M USD
Net Debt/EBITDA2.20
Balance Sheet
Debt/Equity-0.06
Current Ratio8.72
Quick Ratio8.54
Book Value/Sh6.58 USD
Cash/Share6.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.25 USD
Upside (mean)+205.5%
Target Range37.00 USD – 46.00 USD
37.00+205.5% to mean46.00
# Analysts4
Ownership
Shares Out.93.50M
Float51.76M
Insiders15.58%
Institutions77.83%
Short Interest
Short Ratio7.9d
Short % Float3.22%
Short % Out.2.75%
Shares Short2.57M
Short (prev mo.)1.94M
Technical
SMA 5019.10 (-27.6%)
SMA 20020.36 (-32.1%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)776.80K
Avg Vol (10d)590.88K
Technical Indicators
RSI (14)32.8
MACD-1.5100
MACD Signal-1.4749
MACD Hist.-0.0351
BB Upper19.42 USD
BB Middle15.88 USD
BB Lower12.35 USD
BB Width44.48%
ATR (14)1.437 USD
Vol Ratio (20d)1.06x